• 

  Treating ALS: Multiple ALS Drugs Move to Phase 3 Trials
• 

  Dementia Drug Trials and Regulatory Decisions to Watch in 2026
• 

  GLP-1 Semaglutide Fails to Slow Alzheimer’s Despite Biomarker Changes
• 

  Potential First: Pill for Lewy Body Dementia Heads to a Phase 3 Trial
• 

  New Guides: Dementia Risk, Genetics, Diagnosis in Communities of Color
• 

  Could Alzheimer’s Drugs Work Better in Pairs? A New Approach for ‘Mabs’
• 

  Gene Therapy ‘First’: Huntington’s Disease Treated in Early Trial
• 

  Tidal Change: China Takes Alzheimer’s ‘Seaweed Drug’ Off the Market
• 

  Can Stem Cell Therapy Treat Neurodegenerative Disease?
• 

  TRIALS UPDATE: The Latest Alzheimer’s Clinical Trial News (2025.02)
• 

  Stem Cells for Alzheimer’s? Neurologists Weigh In on Longeveron’s New Data
• 

  Alzheimer’s Studies Are Diversifying. Will Scientists Be Able to Finish the Job?
• 

  Can Lifestyle + Medication Do More for Brain Health? FINGER-MET Trial Launches
• 

  Precision Prevention: The Latest on Alzheimer’s Vaccines
• 

  Alzheimer’s Anti-Amyloids Haven’t Wowed—What If They Were Administered Years Earlier?

12Next